CN107089977B - 一种用于治疗艾滋病的药物及其制备方法 - Google Patents
一种用于治疗艾滋病的药物及其制备方法 Download PDFInfo
- Publication number
- CN107089977B CN107089977B CN201710554043.8A CN201710554043A CN107089977B CN 107089977 B CN107089977 B CN 107089977B CN 201710554043 A CN201710554043 A CN 201710554043A CN 107089977 B CN107089977 B CN 107089977B
- Authority
- CN
- China
- Prior art keywords
- added
- aids
- thiazole
- formula
- hiv
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
- 208000030507 AIDS Diseases 0.000 title claims abstract description 19
- 239000003814 drug Substances 0.000 title claims abstract description 14
- 229940079593 drug Drugs 0.000 title claims abstract description 11
- 238000002360 preparation method Methods 0.000 title claims abstract description 8
- 150000001875 compounds Chemical class 0.000 claims abstract description 16
- 239000000126 substance Substances 0.000 claims abstract description 7
- 239000000843 powder Substances 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 8
- 239000003937 drug carrier Substances 0.000 claims description 3
- 239000002775 capsule Substances 0.000 claims description 2
- 239000008187 granular material Substances 0.000 claims description 2
- 238000002347 injection Methods 0.000 claims description 2
- 239000007924 injection Substances 0.000 claims description 2
- 239000006187 pill Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 230000002401 inhibitory effect Effects 0.000 abstract description 13
- 108010061833 Integrases Proteins 0.000 abstract description 11
- 239000002850 integrase inhibitor Substances 0.000 abstract description 5
- 229940124524 integrase inhibitor Drugs 0.000 abstract description 5
- 102000012330 Integrases Human genes 0.000 abstract description 2
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 28
- XKRFYHLGVUSROY-UHFFFAOYSA-N Argon Chemical compound [Ar] XKRFYHLGVUSROY-UHFFFAOYSA-N 0.000 description 20
- 108020004414 DNA Proteins 0.000 description 15
- 230000015572 biosynthetic process Effects 0.000 description 12
- 238000003786 synthesis reaction Methods 0.000 description 12
- 239000011535 reaction buffer Substances 0.000 description 11
- 238000003756 stirring Methods 0.000 description 11
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 10
- 229910052786 argon Inorganic materials 0.000 description 10
- 239000007789 gas Substances 0.000 description 10
- 239000007788 liquid Substances 0.000 description 10
- 239000000243 solution Substances 0.000 description 10
- 238000010792 warming Methods 0.000 description 10
- 102100034343 Integrase Human genes 0.000 description 9
- 238000005160 1H NMR spectroscopy Methods 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000008186 active pharmaceutical agent Substances 0.000 description 7
- 230000000694 effects Effects 0.000 description 7
- 239000007787 solid Substances 0.000 description 7
- 239000002904 solvent Substances 0.000 description 7
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 6
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical compound OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 description 6
- FZWLAAWBMGSTSO-UHFFFAOYSA-N Thiazole Chemical compound C1=CSC=N1 FZWLAAWBMGSTSO-UHFFFAOYSA-N 0.000 description 6
- 238000006243 chemical reaction Methods 0.000 description 6
- 238000000034 method Methods 0.000 description 6
- 239000013642 negative control Substances 0.000 description 6
- 230000008569 process Effects 0.000 description 6
- 108700020129 Human immunodeficiency virus 1 p31 integrase Proteins 0.000 description 5
- 150000001412 amines Chemical class 0.000 description 5
- 150000002500 ions Chemical class 0.000 description 5
- 238000004895 liquid chromatography mass spectrometry Methods 0.000 description 5
- 229910000029 sodium carbonate Inorganic materials 0.000 description 5
- 102000004190 Enzymes Human genes 0.000 description 4
- 108090000790 Enzymes Proteins 0.000 description 4
- 241000713772 Human immunodeficiency virus 1 Species 0.000 description 4
- 239000000872 buffer Substances 0.000 description 4
- 238000011534 incubation Methods 0.000 description 4
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 description 3
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 description 3
- 239000007864 aqueous solution Substances 0.000 description 3
- 230000002255 enzymatic effect Effects 0.000 description 3
- 238000001914 filtration Methods 0.000 description 3
- CZAAKPFIWJXPQT-UHFFFAOYSA-N quinazolin-2-amine Chemical compound C1=CC=CC2=NC(N)=NC=C21 CZAAKPFIWJXPQT-UHFFFAOYSA-N 0.000 description 3
- 239000000758 substrate Substances 0.000 description 3
- 239000011534 wash buffer Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- YBJHBAHKTGYVGT-ZKWXMUAHSA-N (+)-Biotin Chemical compound N1C(=O)N[C@@H]2[C@H](CCCCC(=O)O)SC[C@@H]21 YBJHBAHKTGYVGT-ZKWXMUAHSA-N 0.000 description 2
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 2
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 2
- TXVSPGCFNNZGHC-UHFFFAOYSA-N C1=CC=C(C=C1)C2=NC(=NC3=CC=CC(=C32)C#N)N Chemical compound C1=CC=C(C=C1)C2=NC(=NC3=CC=CC(=C32)C#N)N TXVSPGCFNNZGHC-UHFFFAOYSA-N 0.000 description 2
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- 229940099797 HIV integrase inhibitor Drugs 0.000 description 2
- UFWIBTONFRDIAS-UHFFFAOYSA-N Naphthalene Chemical compound C1=CC=CC2=CC=CC=C21 UFWIBTONFRDIAS-UHFFFAOYSA-N 0.000 description 2
- 206010028980 Neoplasm Diseases 0.000 description 2
- 102000003992 Peroxidases Human genes 0.000 description 2
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 description 2
- 238000002835 absorbance Methods 0.000 description 2
- 230000000903 blocking effect Effects 0.000 description 2
- 201000011510 cancer Diseases 0.000 description 2
- 125000004432 carbon atom Chemical group C* 0.000 description 2
- 229940042399 direct acting antivirals protease inhibitors Drugs 0.000 description 2
- 239000003084 hiv integrase inhibitor Substances 0.000 description 2
- 239000003112 inhibitor Substances 0.000 description 2
- 239000000137 peptide hydrolase inhibitor Substances 0.000 description 2
- 108040007629 peroxidase activity proteins Proteins 0.000 description 2
- 238000012827 research and development Methods 0.000 description 2
- 239000003419 rna directed dna polymerase inhibitor Substances 0.000 description 2
- 241001430294 unidentified retrovirus Species 0.000 description 2
- 238000005406 washing Methods 0.000 description 2
- CCQCRVHVJHAXJB-UHFFFAOYSA-N (4-propan-2-ylphenoxy)boronic acid Chemical compound CC(C)C1=CC=C(OB(O)O)C=C1 CCQCRVHVJHAXJB-UHFFFAOYSA-N 0.000 description 1
- GCMNJUJAKQGROZ-UHFFFAOYSA-N 1,2-Dihydroquinolin-2-imine Chemical compound C1=CC=CC2=NC(N)=CC=C21 GCMNJUJAKQGROZ-UHFFFAOYSA-N 0.000 description 1
- UAIUNKRWKOVEES-UHFFFAOYSA-N 3,3',5,5'-tetramethylbenzidine Chemical compound CC1=C(N)C(C)=CC(C=2C=C(C)C(N)=C(C)C=2)=C1 UAIUNKRWKOVEES-UHFFFAOYSA-N 0.000 description 1
- KOAOERVORSOTKI-UHFFFAOYSA-N 8-chloroquinazoline Chemical compound N1=CN=C2C(Cl)=CC=CC2=C1 KOAOERVORSOTKI-UHFFFAOYSA-N 0.000 description 1
- 229940124321 AIDS medicine Drugs 0.000 description 1
- 235000011330 Armoracia rusticana Nutrition 0.000 description 1
- 240000003291 Armoracia rusticana Species 0.000 description 1
- 208000035473 Communicable disease Diseases 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 208000031886 HIV Infections Diseases 0.000 description 1
- 108010002459 HIV Integrase Proteins 0.000 description 1
- 208000037357 HIV infectious disease Diseases 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 239000004909 Moisturizer Substances 0.000 description 1
- XOFUCUVRLCIUPG-UHFFFAOYSA-N OB(O)OC(C=CC=C1)=C1C1=CC(F)=CC(F)=C1 Chemical class OB(O)OC(C=CC=C1)=C1C1=CC(F)=CC(F)=C1 XOFUCUVRLCIUPG-UHFFFAOYSA-N 0.000 description 1
- TZRXHJWUDPFEEY-UHFFFAOYSA-N Pentaerythritol Tetranitrate Chemical compound [O-][N+](=O)OCC(CO[N+]([O-])=O)(CO[N+]([O-])=O)CO[N+]([O-])=O TZRXHJWUDPFEEY-UHFFFAOYSA-N 0.000 description 1
- 101710115215 Protease inhibitors Proteins 0.000 description 1
- -1 Quinoline azoles Chemical class 0.000 description 1
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 1
- 108010090804 Streptavidin Proteins 0.000 description 1
- 108020005202 Viral DNA Proteins 0.000 description 1
- 229960000583 acetic acid Drugs 0.000 description 1
- 239000002253 acid Substances 0.000 description 1
- 239000000853 adhesive Substances 0.000 description 1
- 230000001070 adhesive effect Effects 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- SMWDFEZZVXVKRB-UHFFFAOYSA-N anhydrous quinoline Natural products N1=CC=CC2=CC=CC=C21 SMWDFEZZVXVKRB-UHFFFAOYSA-N 0.000 description 1
- 239000002259 anti human immunodeficiency virus agent Substances 0.000 description 1
- 238000003149 assay kit Methods 0.000 description 1
- 229960002685 biotin Drugs 0.000 description 1
- 235000020958 biotin Nutrition 0.000 description 1
- 239000011616 biotin Substances 0.000 description 1
- 239000004067 bulking agent Substances 0.000 description 1
- 238000006555 catalytic reaction Methods 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 239000003795 chemical substances by application Substances 0.000 description 1
- 210000000349 chromosome Anatomy 0.000 description 1
- 239000003086 colorant Substances 0.000 description 1
- 238000012937 correction Methods 0.000 description 1
- ZXZBMGGWHWRHPS-UHFFFAOYSA-N cyanato(phenyl)borinic acid Chemical compound N#COB(O)C1=CC=CC=C1 ZXZBMGGWHWRHPS-UHFFFAOYSA-N 0.000 description 1
- 229940127089 cytotoxic agent Drugs 0.000 description 1
- 239000002254 cytotoxic agent Substances 0.000 description 1
- 230000001934 delay Effects 0.000 description 1
- SWXVUIWOUIDPGS-UHFFFAOYSA-N diacetone alcohol Natural products CC(=O)CC(C)(C)O SWXVUIWOUIDPGS-UHFFFAOYSA-N 0.000 description 1
- 201000010099 disease Diseases 0.000 description 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000000890 drug combination Substances 0.000 description 1
- 238000005516 engineering process Methods 0.000 description 1
- 238000006911 enzymatic reaction Methods 0.000 description 1
- 235000019441 ethanol Nutrition 0.000 description 1
- 238000002474 experimental method Methods 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 230000004927 fusion Effects 0.000 description 1
- 229940125777 fusion inhibitor Drugs 0.000 description 1
- 239000012362 glacial acetic acid Substances 0.000 description 1
- 210000005260 human cell Anatomy 0.000 description 1
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 239000004615 ingredient Substances 0.000 description 1
- 230000010354 integration Effects 0.000 description 1
- 238000002372 labelling Methods 0.000 description 1
- 230000031700 light absorption Effects 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- 238000004519 manufacturing process Methods 0.000 description 1
- 230000010534 mechanism of action Effects 0.000 description 1
- 239000012046 mixed solvent Substances 0.000 description 1
- 238000002156 mixing Methods 0.000 description 1
- 238000012986 modification Methods 0.000 description 1
- 230000004048 modification Effects 0.000 description 1
- 230000001333 moisturizer Effects 0.000 description 1
- 150000002825 nitriles Chemical class 0.000 description 1
- 239000012074 organic phase Substances 0.000 description 1
- HXITXNWTGFUOAU-UHFFFAOYSA-N phenylboronic acid Chemical compound OB(O)C1=CC=CC=C1 HXITXNWTGFUOAU-UHFFFAOYSA-N 0.000 description 1
- 239000013641 positive control Substances 0.000 description 1
- 238000012545 processing Methods 0.000 description 1
- 230000002285 radioactive effect Effects 0.000 description 1
- 239000011541 reaction mixture Substances 0.000 description 1
- 238000001953 recrystallisation Methods 0.000 description 1
- 238000010992 reflux Methods 0.000 description 1
- 238000010839 reverse transcription Methods 0.000 description 1
- 150000003839 salts Chemical class 0.000 description 1
- 238000007789 sealing Methods 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 239000011734 sodium Substances 0.000 description 1
- 230000001629 suppression Effects 0.000 description 1
- 238000010998 test method Methods 0.000 description 1
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 description 1
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 1
- 238000012546 transfer Methods 0.000 description 1
- 238000001291 vacuum drying Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Description
化合物 | R | 抑制率(%) |
Ⅰa | 45.1±1.2 | |
Ⅰb | 94.8±0.8 | |
Ⅰc | 63.1±0.8 | |
Ⅰd | 72.8±1.1 | |
Ⅰe | 60.9±0.7 | |
埃替拉韦 | 93.9±1.0 |
Claims (5)
Priority Applications (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201810394600.9A CN108329306A (zh) | 2017-07-09 | 2017-07-09 | 一种用于治疗艾滋病药物的制备方法 |
CN201710554043.8A CN107089977B (zh) | 2017-07-09 | 2017-07-09 | 一种用于治疗艾滋病的药物及其制备方法 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
CN201710554043.8A CN107089977B (zh) | 2017-07-09 | 2017-07-09 | 一种用于治疗艾滋病的药物及其制备方法 |
Related Child Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810394600.9A Division CN108329306A (zh) | 2017-07-09 | 2017-07-09 | 一种用于治疗艾滋病药物的制备方法 |
Publications (2)
Publication Number | Publication Date |
---|---|
CN107089977A CN107089977A (zh) | 2017-08-25 |
CN107089977B true CN107089977B (zh) | 2018-07-31 |
Family
ID=59641611
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201710554043.8A Active CN107089977B (zh) | 2017-07-09 | 2017-07-09 | 一种用于治疗艾滋病的药物及其制备方法 |
CN201810394600.9A Pending CN108329306A (zh) | 2017-07-09 | 2017-07-09 | 一种用于治疗艾滋病药物的制备方法 |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
CN201810394600.9A Pending CN108329306A (zh) | 2017-07-09 | 2017-07-09 | 一种用于治疗艾滋病药物的制备方法 |
Country Status (1)
Country | Link |
---|---|
CN (2) | CN107089977B (zh) |
Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2008077651A1 (en) * | 2006-12-26 | 2008-07-03 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
CN101223143A (zh) * | 2005-05-18 | 2008-07-16 | 惠氏公司 | 作为tpl2激酶抑制剂的3-氰基喹啉以及其制备和应用方法 |
CN101646660A (zh) * | 2007-02-22 | 2010-02-10 | Irm责任有限公司 | 调节g蛋白偶联受体的化合物和方法 |
CN101801379A (zh) * | 2007-10-18 | 2010-08-11 | 诺瓦提斯公司 | 治疗癌症和骨疾病的csf-1r抑制剂 |
WO2016057518A1 (en) * | 2014-10-06 | 2016-04-14 | Kineta, Inc. | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof |
WO2017007694A1 (en) * | 2015-07-06 | 2017-01-12 | Gilead Sciences, Inc. | 6-amino-quinoline-3-carbonitrils as cot modulators |
-
2017
- 2017-07-09 CN CN201710554043.8A patent/CN107089977B/zh active Active
- 2017-07-09 CN CN201810394600.9A patent/CN108329306A/zh active Pending
Patent Citations (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN101223143A (zh) * | 2005-05-18 | 2008-07-16 | 惠氏公司 | 作为tpl2激酶抑制剂的3-氰基喹啉以及其制备和应用方法 |
WO2008077651A1 (en) * | 2006-12-26 | 2008-07-03 | Gilead Sciences, Inc. | Pyrido(3,2-d)pyrimidines useful for treating viral infections |
CN101646660A (zh) * | 2007-02-22 | 2010-02-10 | Irm责任有限公司 | 调节g蛋白偶联受体的化合物和方法 |
CN101801379A (zh) * | 2007-10-18 | 2010-08-11 | 诺瓦提斯公司 | 治疗癌症和骨疾病的csf-1r抑制剂 |
WO2016057518A1 (en) * | 2014-10-06 | 2016-04-14 | Kineta, Inc. | Anti-viral compounds, pharmaceutical compositions, and methods of use thereof |
WO2017007694A1 (en) * | 2015-07-06 | 2017-01-12 | Gilead Sciences, Inc. | 6-amino-quinoline-3-carbonitrils as cot modulators |
Non-Patent Citations (1)
Title |
---|
Reversible Inhibitors of the Gastric (H+/K+)-ATPase.5.Substituted 2,4-Diaminoquinazolines and Thienopyrimidines;Ife, Robert J.等;《J.Med.Chem.》;19951231;第38卷(第14期);第2763-2773页 * |
Also Published As
Publication number | Publication date |
---|---|
CN108329306A (zh) | 2018-07-27 |
CN107089977A (zh) | 2017-08-25 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP4881725B2 (ja) | Tie−2モジュレータと使用方法 | |
CN104024227B (zh) | 抑制脯氨酸羟化酶活性的化合物的晶型及其应用 | |
CN108794411B (zh) | 某些化学实体、组合物及方法 | |
JP5707335B2 (ja) | ジヒドロインデンアミド化合物の製造方法、それらの化合物を含有する医薬組成物、及びプロテインキナーゼ阻害剤としての使用 | |
CN102977014B (zh) | 新的喹啉类化合物及其用途 | |
CN102485721B (zh) | 取代的2,3-二氮杂萘酮化合物及其用途 | |
Khan et al. | Dihydropyrimidine based hydrazine dihydrochloride derivatives as potent urease inhibitors | |
CN107286150A (zh) | N‑杂环类化合物、其中间体、制备方法、药物组合物和应用 | |
JPH08504834A (ja) | 更に付け加えられたピリミジン誘導体およびそれらの製法 | |
ZA200104235B (en) | Aryl and heterocyclyl substituted pyrimidine derivatives as anti-coagulants. | |
MX2007008372A (es) | Ureas disustituidas como inhibidores de cinasa. | |
CN109180642A (zh) | 酞嗪酮类btk抑制剂及其应用 | |
JP2008509187A (ja) | キナーゼ阻害剤としてのトリフルオロメチル置換ベンズアミド | |
Fatima et al. | Synthesis, molecular docking and xanthine oxidase inhibitory activity of 5-aryl-1H-tetrazoles | |
WO2005080392A1 (ja) | ピラゾロキノロン誘導体およびその用途 | |
CN102858763A (zh) | 脯氨酰羟化酶抑制剂及其使用方法 | |
HUE034254T2 (en) | Substituted condensed pyrimidine compounds | |
CN105814039B (zh) | 氟苯基吡唑化合物 | |
CN107501279B (zh) | 呋喃并喹啉二酮类化合物及其医药用途 | |
CN107089977B (zh) | 一种用于治疗艾滋病的药物及其制备方法 | |
CN110343070B (zh) | 一种微管蛋白抑制剂及其制备方法与应用 | |
CN105130984B (zh) | 一种咪唑并吡啶类化合物与在制备pi3k抑制剂中的应用 | |
CN104341416A (zh) | 蛋白酪氨酸激酶抑制剂及其应用 | |
CN105801464A (zh) | 吡咯酰胺类化合物及其制备方法与用途 | |
CN109331018A (zh) | 一种紫杉醇和硝基酞嗪酮btk抑制剂联合用药物组合物及其应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
PB01 | Publication | ||
PB01 | Publication | ||
SE01 | Entry into force of request for substantive examination | ||
SE01 | Entry into force of request for substantive examination | ||
CB03 | Change of inventor or designer information | ||
CB03 | Change of inventor or designer information |
Inventor after: Wang Shanmei Inventor before: Cao Yan |
|
TA01 | Transfer of patent application right | ||
TA01 | Transfer of patent application right |
Effective date of registration: 20180503 Address after: 272699 57 County disease prevention and control center, Liangshan County, Shandong Province Applicant after: Wang Shanmei Address before: 261053 northward 160 meters Road East of Xuanwu Street and Yuhe Road intersection in Kuiwei District, Weifang, Shandong Applicant before: Cao Yan |
|
GR01 | Patent grant | ||
GR01 | Patent grant | ||
TR01 | Transfer of patent right | ||
TR01 | Transfer of patent right |
Effective date of registration: 20210726 Address after: No. 145, Shuibo South Road, Liangshan County, Jining City, Shandong Province Patentee after: Liangshan County Center for Disease Control and Prevention (Liangshan County Health Inspection Center) Address before: 272600 County Center for Disease Control and prevention, No. 57, shuipo West Road, Liangshan County, Shandong Province Patentee before: Wang Shanmei |